Review
Published on 22 Dec 2022
The role and mechanism of claudins in cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1051497
- 8,184 views
- 28 citations
Type at least 3 characters
1,766 articles
Articles
Review
Published on 22 Dec 2022
LINC00324 in cancer: Regulatory and therapeutic implications
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1039366
- 2,083 views
- 7 citations
Case Report
Published on 22 Dec 2022
Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1024677
- 1,675 views
- 3 citations
Original Research
Published on 19 Dec 2022
Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1048482
- 1,573 views
- 2 citations
Review
Published on 16 Dec 2022
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1023177
- 20,171 views
- 127 citations
Review
Published on 16 Dec 2022
The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.947183
- 3,982 views
- 2 citations
Original Research
Published on 14 Dec 2022
Gou Qi Zi inhibits proliferation and induces apoptosis through the PI3K/AKT1 signaling pathway in non-small cell lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1034750
- 3,231 views
- 5 citations
Original Research
Published on 14 Dec 2022
Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1043479
- 2,948 views
- 3 citations
Original Research
Published on 14 Dec 2022
Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1027792
- 2,132 views
- 16 citations
Original Research
Published on 14 Dec 2022
Knowledge mapping of alternative splicing of cancer from 2012 to 2021: A bibliometric analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1068805
- 3,944 views
- 3 citations
Review
Published on 13 Dec 2022
Targeted therapy of RET fusion-positive non-small cell lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1033484
- 9,597 views
- 8 citations
Correction
Published on 13 Dec 2022
Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1113289
- 789 views
Case Report
Published on 12 Dec 2022
Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1042525
- 1,871 views
- 2 citations
Case Report
Published on 12 Dec 2022
Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1086677
- 3,239 views
- 4 citations
Original Research
Published on 09 Dec 2022
RRBP1 depletion of bone metastatic cancer cells contributes to enhanced expression of the osteoblastic phenotype
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1005152
- 2,369 views
Original Research
Published on 08 Dec 2022
DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1052163
- 2,762 views
- 8 citations